ReviewExpert review of vaccines2015
Middle East respiratory syndrome: obstacles and prospects for vaccine development.
Review in Expert review of vaccines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Next-Generation Nucleic Acid-Based Diagnostics for Viral Pathogens: Lessons Learned from the SARS-CoV-2 Pandemic.Microorganisms · 2025Review
- Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy.Pharmaceutics · 2023Review
- Vaccine Innovation Meta-Model for Pandemic Contexts.Journal of pharmaceutical innovation · 2023Article
- Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting.Nano today · 2022Article
- Designing multi-epitope based peptide vaccine targeting spike protein SARS-CoV-2 B1.1.529 (Omicron) variant using computational approaches.Structural chemistry · 2022Article
- Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.Human vaccines & immunotherapeutics · 2021Article
- Stockholm Syndrome: How to come to peace with our captor.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2020Article
- Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2.Scientific reports · 2020Article
- Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination.Life sciences · 2020Review
- Immune responses during COVID-19 infection.Oncoimmunology · 2020Review
- Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity.Cell reports. Medicine · 2020Article
- Burden of Middle East respiratory syndrome coronavirus infection in Saudi Arabia.Journal of infection and public health · 2020Article
- Novel Coronavirus (nCoV): a Bitter Old Enemy in a New Avatar.SN comprehensive clinical medicine · 2020Review
- Review
- Vaccines for epidemic infections and the role of CEPI.Human vaccines & immunotherapeutics · 2017Review
- MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.Oncotarget · 2017Article
- MERS-CoV spike protein: Targets for vaccines and therapeutics.Antiviral research · 2016Review
- Control Measures for Human Respiratory Viral Infection.Seminars in respiratory and critical care medicine · 2016Review
- Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.Emerging infectious diseases · 2016Article
- Coronaviruses - drug discovery and therapeutic options.Nature reviews. Drug discovery · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The recent emergence of Middle East respiratory syndrome (MERS) highlights the need to engineer new methods for expediting vaccine development against emerging diseases. However, several obstacles prevent pursuit of a licensable MERS vaccine. First, the lack of a suitable animal model for MERS complicates the in vivo testing of candidate vaccines. Second, due to the low number of MERS cases, pharmaceutical companies have little incentive to pursue MERS vaccine production as the costs of clinical trials are high. In addition, the timeline from bench research to approved vaccine use is 10 years or longer. Using novel methods and cost-saving strategies, genetically engineered vaccines can be produced quickly and cost-effectively. Along with progress in MERS animal model development, these obstacles can be circumvented or at least mitigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.